Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: In patients with hypercalcaemia, assessment of urinary calcium excretion helps differentiate primary hyperparathyroidism (PHPT) from familial hypocalciuric hypercalcaemia (FHH). For this, 24 h calcium to creatinine clearance ratio (CCCR) is recommended, but others tests like random CCCR, 24 h urine calcium excretion (UCE), and calcium to creatinine ratio (CR) are also frequently used.

Objective: The survey objective was to evaluate current practice among UK endocrinologists and surgeons.

Methods: A web-based anonymous cross-sectional survey, consisting of eight multiple-choice questions was developed using Survey Monkey. The survey was disseminated to members of British Association of Endocrine and Thyroid Surgeons (BAETS) and Society for Endocrinology (SfE) between November 20, 2025 and December 19, 2024.

Results: Two hundred and sixty-six responses from 210 endocrinologists and 56 surgeons were received (85% consultants). Respondents worked in both university (48.9%) and district hospitals (47.7%). The most commonly performed urine calcium test in hypercalcaemic patients was 24 h UCE (58.6%), but for PHPT versus FHH differentiation, the most preferred test was 24 h CCCR (43.6%), followed by random CCCR (24.8%), 24 h UCE (14.3%), and CR (16.5%). Of respondents who had experience with using CCCR (n = 235), most (55.6%) used a cut-off of > 0.01 to rule out FHH, while > 0.02 cut off was used by 26.7% respondents. Most clinicians (70.3%) used albumin-adjusted calcium for CCCR calculation, and 71.4% respondents considered vitamin D levels ≥ 50 nmol/L to be adequate for urinary calcium measurement.

Conclusion: The survey provides valuable insight into current UK practice. 24 h and random CCCR are the most commonly used tests to exclude FHH, but overall, practice varies widely.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cen.70008DOI Listing

Publication Analysis

Top Keywords

urinary calcium
12
random cccr
12
patients hypercalcaemia
8
calcium excretion
8
calcium creatinine
8
urine calcium
8
current practice
8
24 h uce
8
calcium
7
cccr
7

Similar Publications

is gene that encodes one of the cytochrome P450 superfamily enzymes involved in the breakdown of 1,25-dihydroxyvitamin D3. Genetic variants in lead to a range of phenotypical and biochemical presentations, including idiopathic infantile hypercalcemia, elevated concentrations of 1,25 dihydroxy vitamin D, adult onset nephrocalcinosis, hypercalciuria, hypercalcemia and nephrolithiasis. Here we present an adult female, aged 68 years of age who presented with intermittent abdominal pain, with a past medical history of hypertension.

View Article and Find Full Text PDF

Kidney stones have a high recurrence rate-10% within 5 years and 50% within 10. Crystalluria reflects the urinary physicochemical environment and may serve as a recurrence marker, but key crystals like brushite are rarely detected under ambient conditions. This study aimed to identify novel recurrence markers by inducing crystallization through urine cooling and analyzing crystal composition.

View Article and Find Full Text PDF

Background: Kidney stone formation is driven by an imbalance between lithogenic substances and crystallization inhibitors. Current guidelines recommend a 24-h urine collection in patients with kidney stone disease to assess the risk of stone formation and monitor therapy compliance. However, real-world data on adherence to these guidelines remain limited and outdated.

View Article and Find Full Text PDF

A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use.

Endocrinol Diabetes Metab Case Rep

July 2025

Department of Internal Medicine, Medical City Arlington, Arlington, Texas, USA.

Summary: Hypercalcemia is a prevalent electrolyte disturbance commonly associated with primary hyperparathyroidism, cancer, or medication adverse effects. Thiazide diuretics reduce urinary calcium excretion, increasing calcium reabsorption and hypercalcemia. Tirzepatide, a dual GIP and GLP-1 receptor agonist, is increasingly used for type 2 diabetes and obesity.

View Article and Find Full Text PDF

A 63-year-old woman underwent living-donor kidney transplantation three years earlier for end-stage renal disease due to diabetic nephropathy, with her younger sister as the donor. She was prescribed calcium polystyrene sulfonate for the management of hyperkalemia, which had been discontinued two years earlier. At this time, she developed recurrent abdominal and urinary symptoms, which were managed empirically with antibiotics.

View Article and Find Full Text PDF